Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292665 | 0.89 | KDM4E (0.50) | ABCB1KDM4EALDH1A1 | |
| SCHEMBL6292851 | 0.86 | RAB9A (0.39) | KDM4E | |
| SCHEMBL6291795 | 0.85 | ALDH1A1 (0.46) | ABCB1MTNR1AMTNR1BHTR1ADRD2 | |
| SCHEMBL6295639 | 0.85 | ADRA1A (0.47) | TAAR1MTNR1AMTNR1BAOC3MEN1 | |
| SCHEMBL6292623 | 0.79 | ALDH1A1 (0.44) | TAAR1HTR1AKDM4EALDH1A1 | |
| SCHEMBL6292638 | 0.77 | IAPP (0.41) | KDM4EALDH1A1 | |
| SCHEMBL7535470 | 0.75 | TAAR1 (0.56) | TAAR1ABCB1MTNR1AMTNR1BSIGMAR1 | |
| SCHEMBL28049956 | 0.74 | TAAR1 (0.51) | TAAR1ABCB1MTNR1AMTNR1BSIGMAR1 | |
| SCHEMBL30596267 | 0.73 | KCNA5 (0.51) | MEN1KMT2AKDM4EALDH1A1KCNH2 | |
| SCHEMBL2230732 | 0.73 | KCNA5 (0.51) | MEN1KMT2AKDM4EALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846817-B2 | Nicotine receptor ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030027810-A1 | Nicotine receptor ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-02-06 | — | — | US | disclosed |
| WO-2000073269-A2 | NICOTINE RECEPTOR LIGANDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027810-A1 | Nicotine receptor ligands | CHRNA1, CHRNB1, CHRNA9 | TAAR1 46/4885ABCB1 1969/4885MTNR1A 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.